(TheNewswire)
-
Chief Executive Colin Keating topresent in London at PSYCH Symposium and to be interviewed by BBC Newsthis week
-
MindBio reports on the success ofPlant Medicine Week in Malta and provides video recording of keynotepresentation
-
Co-founder Justin Hanka conductingnon-deal broker roadshow in Canada and appearing on investor panel anddelivering keynote presentation in Washington DC in May.
-
MindBio wins prestigiouscommunications award
-
Recent completion of Phase 1 ClinicalTrials with data analysis now underway ahead of preparations for Phase2 Clinical Trials in patients with Major Depressive Disorder andlate-stage cancer patients
Vancouver, British Columbia – TheNewswire - May 11, 2022 –Blackhawk Growth Corp. (CSE:BLR ) ( Frankfurt:0JJ) (the “ Company ” or“ Blackhawk ”) is pleased to report an acceleration and expansion ofglobal market communication activities by its wholly-owned subsidiary,MindBio Therapeutics Pty. Ltd. (“ MindBio ”).
MindBio was recently a headline sponsor at PlantMedicine Week in Malta. MindBio Co-Founder Justin Hanka delivered akeynote presentation to attendees outlining MindBio’s ambition tochange the course of mental health treatments and prevent suicide. He explains MindBio’s investment thesis in the sector pioneeringnovel psychedelic microdosing treatments through it’s world firstclinical trials. You can view the newly released video of JustinHanka’s keynote presentation on YouTube here.
This week MindBio is in London at the PSYCH Symposiumand MindBio Chief Executive Officer, Colin Keating will be presentingwith other industry leaders on a panel discussing the future ofpsychedelic medicines and will be interviewed by BBC News.
Next week, MindBio Co-Founder Justin Hanka isconducting a non-deal roadshow with brokers and investors in Vancouverand Toronto. After that, he will head to Washington DC (USA) for thePsychedelic Therapeutics and Drug Development Conference. Mr. Hanka isparticipating in an investor panel with leading industry experts andis also delivering a keynote presentation on MindBio’s world firstclinical trials microdosing LSD.
MindBio remains the only organization in the world tohave successfully received government approvals to administer LSD(lysergic acid diethylamide) to patients in clinical trials who takethe drug out in the community and at home in the same way they wouldtake any other medication. The Company recently announced the completion of Phase 1 clinicaltrials .
MindBio is accelerating its global communicationsstrategy to advance the company’s narrative in mental healthtreatments and recently was recognised with a Horizon Active Gold MarketingAward for an psychedelics explainer videoalongside an impressive line-up of household names, includingPorsche.
“MindBio is leading the way in psychedelicmicrodosing clinical trials.” said Frederick Pels, CEO of Blackhawk.“With the recent successful completion of MindBio’s Phase 1clinical trial, the MindBio team is now accelerating its globalcommunications strategy as it unravels the datafrom clinical trials and prepares for Phase 2 Clinical Trials andprogressing towards commercialization,”
About Blackhawk Growth
Blackhawk is an investment holding company looking tocreate substantial value for its shareholders through the acquisitionand development of high growth companies. It has focused itsinvestments in the health, cannabis and cannabidiol industries in bothCanada and the United States. Its portfolio of companies includes SacPharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods,MindBio Therapeutics, Digital Mind Therapeutics, Blum Distributors aswell as an equity position in Gaia Grow Corp. (CSE:GAIA).
The Company diligently posts updates through videosfrom the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk groupsupporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com .
For further information please contact:
Frederick Pels, Chief ExecutiveOfficer
(403)-991-7737
fred@ blackhawkgrowth.com
Cautionary NoteRegarding Forward-Looking Statement
All statements in this pressrelease, other than statements of historical fact, are “forward-looking information”with respect to the Company within the meaning of applicablesecurities laws, including with respect to transaction and futureoperations of MindBio Therapeutics Pty Ltd. The Company providesforward-looking statements for the purpose of conveying informationabout current expectations and plans relating to the future andreaders are cautioned that such statements may not be appropriate forother purposes. By its nature, this information is subject to inherentrisks and uncertainties that may be general or specific and which giverise to the possibility that expectations, forecasts, predictions,projections or conclusions will not prove to be accurate, thatassumptions may not be correct and that objectives, strategic goalsand priorities will not be achieved. These risks and uncertaintiesinclude but are not limited those identified and reported in theCompany’s public filings under the Company’s SEDAR profile atwww.sedar.com. Although the Company has attempted to identifyimportant factors that could cause actual actions, events or resultsto differ materially from those described in forward-lookinginformation, there may be other factors that cause actions, events orresults not to be as anticipated, estimated or intended. There can beno assurance that such information will prove to be accurate as actualresults and future events could differ materially from thoseanticipated in such statements. The Company disclaims any intention orobligation to update or revise any forward-looking information,whether as a result of new information, future events or otherwiseunless required by law.
Copyright (c) 2022 TheNewswire - All rights reserved.